Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Statement [Abstract]
Net loss attributable to Mangoceuticals, Inc.	$ (1,999,694)	$ (1,799,460)	$ (6,758,630)	$ (6,644,370)
Other comprehensive expense
Foreign currency adjustments	(497)		(1,663)
Comprehensive loss	(2,000,191)	(1,799,460)	(6,760,293)	(6,644,370)
Other comprehensive expense
Net loss attributed to non-controlling interest	(461)		(837)
Comprehensive loss attributable to Mangoceuticals, Inc.	$ (1,999,730)	$ (1,799,460)	$ (6,759,456)	$ (6,644,370)